BridgeMD
New treatment option for Parkinson's Disease (PD)
Official title Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients
ClinicalTrials.gov ID: NCT06975059
What this study is testing
- What it's testing
- Gait changes in Parkinson's disease are complex, variable, and difficult to detect during short clinic assessments. The aim of this study is to collect gait measurements in Parkinson's patients through sensors in a novel shoe device, NUSHU by Magnes AG.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Parkinson's Disease:
- Male or female ≥ 18 years of age.
- A diagnosis of Parkinson's disease
- Able to give written informed consent (as determined by the investigator)
- Can converse in English and read and perform all study activities
You likely can't join if
- Diagnosis of an atypical parkinsonism syndrome, drug-induced parkinsonism, essential tremor, or other diagnoses that explain movement symptoms other...
- A diagnosis of significant CNS disease other than PD such as stroke, multiple sclerosis, epilepsy
- Persons with disorders other than PD significantly affecting gait as determined by the investigator
- History of MRI brain scan indicative of clinically significant abnormality as determined by the investigator
- Inability to wear treatment device
- Unable to ambulate independently at least with assistive walking device but without additional person assistance
See the full eligibility criteria
- Parkinson's Disease:
- Male or female ≥ 18 years of age.
- A diagnosis of Parkinson's disease
- Able to give written informed consent (as determined by the investigator)
- Can converse in English and read and perform all study activities
- Has willingness and ability to comply with study requirements
- Diagnosis of an atypical parkinsonism syndrome, drug-induced parkinsonism, essential tremor, or other diagnoses that explain movement symptoms other than PD
- A diagnosis of significant CNS disease other than PD such as stroke, multiple sclerosis, epilepsy
- Persons with disorders other than PD significantly affecting gait as determined by the investigator
- History of MRI brain scan indicative of clinically significant abnormality as determined by the investigator
- Inability to wear treatment device
- Unable to ambulate independently at least with assistive walking device but without additional person assistance
- Pregnant or planning pregnancy within study timeframe
- Montreal Cognitive Assessment (MoCA) score \< 22 at screening
- Resides in a nursing home or assisted care facility Healthy Controls: Inclusion Criteria:
- Male or female ≥ 18 years of age.
- No neurological disease or other significant gait impairment as deemed by the study investigator
The study team makes the final eligibility decision.
Where it's taking place
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New York, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.